​
​

Syros Pharmaceuticals Ownership | Who Owns Syros Pharmaceuticals?

OverviewForecastRevenueFinancialsChartTranscripts

Syros Pharmaceuticals Ownership Summary

100.00% retail investors. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.44% of its assets in Syros Pharmaceuticals shares.

SYRS Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockSyros Pharmaceuticals--100.00%
SectorHealthcare Stocks 47.06%8.01%44.93%
IndustryBiotech Stocks 44.97%7.82%47.21%

Institutional Shareholders

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 20231-219--125000.00%----
Dec 31, 20221-66.67%219-99.98%-0.01%--100.00%--100.00%
Sep 30, 20223-95.16%881,719-97.52%31.94%1-96.30%1-95.65%
Jun 30, 202262-31.87%35,569,373-20.26%124.98%27-32.50%23-25.81%
Mar 31, 2022911.11%44,604,457-12.84%164.74%40-4.76%31-3.13%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv654.18K2.44%-
Kennedy Micro Cap328.08K1.22%1.64K
Vanguard Institutional Extnd Mkt Idx Tr257.63K0.96%-
Fidelity Extended Market Index102.37K0.38%-24.20K
iShares Micro-Cap ETF56.60K0.21%-
Bridgeway Ultra-Small Company Market50.67K0.19%-
Kennedy Micro Cap Opportunities47.18K0.18%170.00
BlackRock Extended Equity Market K45.36K0.17%-19.00
Fidelity Total Market Index39.96K0.15%-
Fidelity Series Total Market Index23.73K0.09%-5.77K

Recent Insider Transactions

DateNameRoleActivityValue
Sep 11, 2024Chee Conley President & CEOBuy$85.42K
Sep 11, 2024Haas Jason Chief Financial OfficerBuy$30.45K
Sep 10, 2024Chee Conley President & CEOBuy$75.26K
Sep 10, 2024Haas Jason Chief Financial OfficerBuy$54.79K
Sep 12, 2024Haas Jason Chief Financial OfficerBuy$76.01K

Insider Transactions Trends

DateBuySell
2024 Q35-
2024 Q2-3
2024 Q1--
2023 Q412
2023 Q3-2

SYRS Ownership FAQ

Who Owns Syros Pharmaceuticals?

Syros Pharmaceuticals shareholders are primarily institutional investors at 0.00%, followed by 0% insiders and 0% retail investors. The average institutional ownership in Syros Pharmaceuticals's industry, Biotech Stocks , is 44.97%, which Syros Pharmaceuticals falls below.

Does Blackrock own Syros Pharmaceuticals?

BlackRock is not among the top 10 institutional shareholders of Syros Pharmaceuticals.

Who is the top mutual fund holder of Syros Pharmaceuticals shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Syros Pharmaceuticals shares, with 2.44% of its total shares outstanding invested in 654.18K Syros Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools